HemaQuest Pharmaceuticals (Newton, MA) a clinical-stage small molecule company focused on hemoglobin disorders such as sickle cell disease, beta thalassemia, and viral-associated disease such as HPV, EBV and HIV, closed a $12M Series B financing. Participants include Aberdare Ventures, De Novo Ventures, Forward Ventures and Lilly Ventures.

Sangart (San Diego, CA) a clinical-stage artificial blood substitute focused on targeting oxygen delivery to tissues that are insufficiently oxygenated, closed a $50M Series F financing, the final tranche of the $100M round. Participants include Leucadia National who owns approximately 92% of the company after investing approximately $146.2M since 2003.